Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Prognostic significance of t(11;14) in multiple myeloma

Susan Bal • 14 Dec 2020
ASH 2020
Multiple Myeloma

Susan Bal, MD, MBBS, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, shares the findings of a real-world investigation into the characteristics and outcomes of t(11;14) multiple myeloma patients. Progression-free survival (PFS) and overall survival (OS) were compared for t(11;14)+ and t(11;14)- patients, as well as other common genetically-defined subgroups. The analysis found that patients with t(11;14)+ had a worse PFS and OS compared to patients with t(11;14)-. The presence of the t(11;14) translocation also negatively impacted prognosis in myeloma with del(17p). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Susan Bal

1:31
BCL2 inhibition with sonrotoclax for treating t(11;14) multiple myeloma
Susan Bal • 9 Dec 2023
2:09
Using MRD to understand the response to autoSCT in patients with multiple myeloma
Susan Bal • 9 Dec 2023
1:42
Immune profiling & MRD negativity of NDMM treated with quadruplet induction+autoSCT: MILESTONE trial
Susan Bal • 9 Dec 2023
2:14
BMS-986393 CAR T-cell therapy for R/R multiple myeloma: results of a Phase I trial
Susan Bal • 9 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals